Grifols launches XEMBIFY® 20% subcutaneous immunoglobulin, a new Primary Immunodeficiency treatment

- **XEMBIFY® is formulated for a wide range of Primary Immunodeficiency (PI) patient types, including those with risk factors**
- **Grifols, a frontrunner in disease treatment with immunoglobulins, is committed to R+D+i to benefit patients and healthcare professionals**
- **In addition to the U.S. launch of XEMBIFY®, the company is working to obtain additional approvals in Canada, Europe and other global markets**

**Barcelona, December 12, 2019.**- Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest immunoglobulin (IG) innovation, XEMBIFY® (immune globulin subcutaneous human-klhw), the company’s first 20% subcutaneous immunoglobulin therapy for the treatment of patients 2 years of age and older with primary immunodeficiency (PI).

With proven safety, efficacy, and tolerability, XEMBIFY® offers subcutaneous administration to patients in the treatment of PI, which are rare and chronic genetic disorders that occur in people born with an impaired or absent immune system. There are roughly 150,0001 patients with PI who may be appropriate for IG therapy.

Strengthening Grifols’ growing IG portfolio for PI treatment, XEMBIFY® features a balanced formulation for the treatment of a wide range of PI patients, inclusive of those with risk factors, such as diabetes or cardiac impairment. XEMBIFY® was approved by the U.S. Food and Drug Administration (FDA) in July 2019.

The launch of XEMBIFY® solidifies Grifols as a frontrunner in disease treatment with immunoglobulins and reflects the company’s commitment to R+D+i, which has enabled it to expand further its industry-leading portfolio of plasma-derived medicines to benefit patients and healthcare professionals. The company is currently working with healthcare authorities to obtain approval for XEMBIFY® in Canada, Europe and other global markets.

“Today marks an exciting milestone as we launch XEMBIFY®, an important new medicine for PI patients in the United States,” said Joel Abelson, President, Bioscience Commercial Division. “Adding to our existing IG portfolio, XEMBIFY® is another example of Grifols executing on our mission to improve the lives and well-being of people who suffer from serious, rare and chronic diseases.”

“People living with PI benefit from having a number of different treatment and dosing options, ultimately giving them an opportunity to tailor treatment to meet their specific needs,” said John G. Boyle, President and Chief Executive Officer of the Immune Deficiency Foundation.

---

“Adding XEMBIFY® to the list of available treatments for PI will give members of our community greater flexibility in managing their care and reducing the impact PI has on their lives.”

**Investor contact:**

Investor Relations
inversores@grifols.com - investors@grifols.com
Phone number: +34 93 571 02 21

**Media contacts:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raquel Lumbreras</td>
<td><a href="mailto:Raquel_lumbreras@duomocomunicacion.com">Raquel_lumbreras@duomocomunicacion.com</a></td>
</tr>
<tr>
<td>Borja Gómez</td>
<td><a href="mailto:Borja_gomez@duomocomunicacion.com">Borja_gomez@duomocomunicacion.com</a></td>
</tr>
<tr>
<td>Duomo Comunicación – Grifols PR office</td>
<td>Tel. +34 91 311 92 89 - 91 311 92 90</td>
</tr>
<tr>
<td>Brad Pick</td>
<td>Grifols Corporate Communications</td>
</tr>
<tr>
<td></td>
<td><a href="mailto:Brad.pick@grifols.com">Brad.pick@grifols.com</a></td>
</tr>
</tbody>
</table>

**About Grifols**

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

**LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or
circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.